Search
NOX-100
go.drugbank.com/drugs/DB05799InvestigationalNOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.
Erythroxylum catuaba bark
go.drugbank.com/drugs/DB14300Investigational[A215262] The infusion is thought to carry stimulant and aphrodisiac effects,[A215262] and catuaba made specifically with _Trichilia catigua_ has been investigated for use in depression.[A215267] … "Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the _Erythroxylum_ genus, though this name is also applied to infusions of plants belonging to other genera
Technetium Tc-99m sulfur colloid
go.drugbank.com/drugs/DB09397ApprovedThis is possible as Technetium-99m decays by isomeric transition to technetium-99 through the release of a gamma ray. … intended usage, Technetium 99m sulfur colloid enters the capillaries and is transported to the lymph nodes (subcutaneous injection), mixes with peritoneal fluid (intraperitoneal injection), is taken up by
Tauroursodeoxycholic acid
go.drugbank.com/drugs/DB08834ApprovedInvestigationalWithdrawn[A249070] It is a taurine conjugate of [ursodeoxycholic acid] [A249065] with comparable therapeutic efficacy and safety,[A249070] but a much higher hydrophilicity.
Olipudase alfa
go.drugbank.com/drugs/DB12835ApprovedInvestigational[A251590] It was later approved by the European Commission on June 28, 2022 [L42740] and by the FDA on August 31, 2022.[L43145] … [L42740] ASMD is a rare lysosomal storage disease caused by mutations in the SMPD1 gene, leading to a deficiency in acid sphingomyelinase and the abnormal accumulation of the primary ASM substrate, sphingomyelin
Sofpironium
go.drugbank.com/drugs/DB19325Approved[L51108,L51109] Sofpironium bromide (Sofdra) was approved by the FDA in June 2024 for the topical treatment of primary axillary hyperhidrosis. … [L51109] Soft drugs are designed to reduce systemic toxicity while enhancing local efficacy by employing retrometabolic drug design, in which a molecule contains a metabolically sensitive moiety that promotes
Tramazoline
go.drugbank.com/drugs/DB13064InvestigationalTramazoline is under investigation in clinical trial NCT01601509 (Nasal Tramazoline and Dexamethazone in Obstructive Sleep Apnea (OSA) Patients Tramazoline and).
Cystine
go.drugbank.com/drugs/DB00138ApprovedInvestigationalNutraceuticalWithdrawnA covalently linked dimeric nonessential amino acid formed by the oxidation of cysteine. Two molecules of cysteine are joined together by a disulfide bridge to form cystine.
SLV319
go.drugbank.com/drugs/DB05077ExperimentalSLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor.
MDX-1303
go.drugbank.com/drugs/DB05945InvestigationalMDX-1303 is a fully human antibody against the inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium, and targets a protein component of these lethal